GlobalData on MSN
FDA accepts Otsuka’s centanafadine application for ADHD treatment
The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.
The MarketWatch News Department was not involved in the creation of this content.-- Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents ...
Attention-deficit/hyperactivity disorder (ADHD) is a common but complex neurodevelopmental condition characterized by symptoms of inattention, hyperactivity, and ...
Focus ADHD is an online psychiatric clinic based in Des Moines, Iowa, offering personalized treatment for adult professionals living with ADHD. The clinic provides expert medication management, ...
Long-term methylphenidate use in childhood links to higher adult BMI and slightly shorter height, underscoring the need for ...
This article was reviewed by Lynn Marie Morski, MD, JD. Key Takeaways: ADHD and menopause symptoms can overlap, and one ...
With an expiration date still more than a year away, here's what the latest details reveal.
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition that causes hyperactivity and impulsivity in children and adults. If left untreated ...
TwistedSifter on MSN
New study shows that women get an ADHD diagnosis five years later than men, even when their symptoms arise at the same age
Gendered diagnosis screening may be necessary.
Boys who stopped ADHD treatment at higher risk for negative consequences. Oct. 16, 2012 — -- Young boys who discontinue treatment for attention deficit hyperactivity disorder (ADHD) are featured ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results